

Emcure Pharmaceuticals Announces Strong Q3FY25 with 18% Revenue Growth and 30% Profit After Tax Growth

- Revenue from operations at Rs 1,963 Cr, up 17.7% YoY
- EBITDA margins at 18.4% with EBITDA up 23.2% YoY
- PAT at 156Cr, up 30.3% YoY
- Domestic business sales at 888 Cr, up 12.0% YoY
- International business sales at 1,075 Cr, up 23.0% YoY

Pune, February 6, 2025: Emcure Pharmaceuticals Ltd. (BSE:544210, NSE: EMCURE) today announced its unaudited consolidated financial results for the quarter ended December 31st, 2024.

The quarter saw strong growth led by the International businesses that grew 23% YoY. The Canadian business continues to perform well, achieving a 34% YoY growth and the Mantra subsidiary is now fully integrated. Company’s Rest of the World (RoW) market business grew a robust 40% YoY aided by strong growth in our non-ARV segment. The company continues to see traction in its key focus markets led by its differentiated product portfolio. Emcure’s Domestic business grew by over 12% to ₹ 888 Cr, led by a steady performance in the base business and aided by in-licensed products.

Commenting on the results, Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals Ltd., said, “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portfolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portfolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.”

Revenue break-up:

Rs Cr.	3Q25	3Q24	YOY%	2Q25	QOQ%
Revenue from operations	1,963	1,668	17.7%	2,002	-2.0%
Domestic	888	794	12.0%	933	-4.8%
International	1,075	874	23.0%	1,069	0.5%
Rest of the world	365	260	40.4%	411	-11.3%
EU	358	351	1.9%	362	-1.2%
Canada & Others	352	263	33.8%	296	18.8%

Contd.

Performance Summary (Consolidated)

Rs Cr	3Q25	3Q24	YOY%	2Q25	QOQ%
Revenue from operations	1,963	1,668	17.7%	2,002	-2.0%
Material Cost	783	622	25.9%	789	-0.8%
Gross Profit	1,180	1,046	12.8%	1,213	-2.8%
Gross Profit Margins	60.1%	62.7%		60.6%	
Employee Costs	367	332	10.5%	356	3.2%
Other expenses	451	420	7.4%	477	-5.4%
EBITDA	362	294	23.2%	381	-5.0%
EBITDA Margins	18.4%	17.6%		19.0%	
Other Income	4	29		36	
Depreciation and Amortisation	97	84		97	
Finance Costs incl. Forex loss	39	61		46	
Exceptional Items	0	7		0	
Profit Before Tax (PBT)	230	171	34.5%	273	-15.9%
Tax	74	51		72	
Profit After Tax (PAT)	156	120	30.3%	202	-22.6%
PAT Margins	8.0%	7.2%		10.1%	

About Emcure Pharmaceuticals Ltd:

Emcure Pharmaceuticals Ltd. (EPL) is a leading Indian pharma company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 12th largest pharma company in India in terms of Domestic Sales for MAT June 2024. Emcure is present in 70+ countries globally including Europe and Canada.

Contact:

Media

corpcomm@emcure.com

Investor Relations

investor.relations@emcure.com

Details of the Earnings Call:

- **Date:** Thursday, February 6, 2025
- **Time:** 5:30 p.m. – 6:30 p.m. (IST)
- **Dial-In Numbers:**
 - Universal Access: [+91 22 6280 1220](tel:+912262801220) / [+91 22 7115 8122](tel:+912271158122)
 - USA: 1 866 746 2133
 - UK: 0 808 101 1573
 - Singapore: 800 101 2045
 - Hong Kong: 800 964 448